Chronic obstructive pulmonary disease (COPD), 255, 261
Ciprofloxacin (Cipro), 238, 239t, 243 t, 404 t
Circulation, 349
Circulatory disorders
anticoagulants and antiplatelet drugs, 364–366
antilipemics, 366–368, 367t
overview, 364
peripheral vascular disease, 368–369
thrombolytics, 366
Cisapride (Propulsid), 343
Cisplatin (Platinol)
interaction with aminoglycosides, 230
interaction with vancomycin, 227
Clarithromycin, 223t, 243 t, 407 t
Clemastine fumarate (Tavist), 259t
Clindamycins, 224–226, 226t
drug-drug interactions, 225
interaction with chloramphenicol, 236
nursing diagnosis, 225–226
Clofibrate (Atromid-S), 368
Clomipramine (Anafranil), 299t
Clonazepam, 70t, 294
Cloxacillin (Tegopen), 211t
CNS depressants
anesthetic agents, 276–277, 278t
barbiturates, 275, 275t–276t
local anesthetics, 280, 280t
overview, 273
sedative-hypnotics, 273–274
spinal anesthesia, 280–281
topical anesthetic agents, 278–279, 279t
Cocaine, 69t, 280 t
contraindicated with breastfeeding, 55
days detectable in urine, 68t
Codeine, 310t
Colestipol (Colestid), 368
interaction with penicillin, 214
interaction with tetracyclines, 233
interaction with vancomycin, 227
Collaborative intervention, 50
Colloids, 160–161
Common cold
antihistamines (H 1 blockers), 257, 258t–259t
cough preparations, 258
decongestants (sympathomimetic amines), 257–258
description, 256–257
expectorants, 258
Comprehensive Drug Abuse Prevent and Control Act
(1970), 3
Conjunctivitis, 400–401
Constipation
bulk-forming laxatives, 339
emollients, 340
osmotics (saline), 338
overview, 337–338
stimulants (contact or irritants), 338–339
Copaxone (glatiramer acetate injection), 291
COPD (chronic obstructive pulmonary disease), 255,
261
anti-inflammatories, 265
bronchodilators, 264–265
expectorants, 265–266
leukotriene modifiers, 265
mast stabilizer drugs, 266
Copolymer 1, 291
Corneal abrasion, 401
Corticosteroids, 199
multiple sclerosis, 291
Corticotropin (Acthar), 388
Cough preparations, 258
Coumarin
interaction with cephalosporins, 217
Cromolyn (Intal), 266
Crystalloids, 160
Cultural aspects of substance abuse, 72–73
Cultural influences in drug administration
ethnic considerations, 53
overview, 52–53
Cumulative effect, 86
Cyclandelate (Cyclate), 369
Cyclobenzaprine (Flexeril), 290
Cyclophosphamide
contraindicated with breastfeeding, 55
Cycloserine (Seromycin), 243t, 244
Cyclosporine (Sandimmune), 325
contraindicated with breastfeeding, 55
interaction with aminoglycosides, 230
interaction with macrolides, 224
interaction with vancomycin, 227D
Dalteparin (Fragmin), 365
Dantrolene (Dantrium), 290
Debrox, 406(^442) Index